Cystatin C is a marker for acute kidney injury, but not for mortality among COVID-19 patients in Mexico.

Background: Patients infected with SARS-CoV-2 can develop acute kidney injury (AKI), associated with adverse clinical outcomes. In Mexico, an AKI incidence of 60.7% was reported in patients with COVID-19.